Clinical Trial Starts In Autoimmune/Inflammatory Diseases Shift From Rheumatology To Asthma And COPD Disorders
Citeline, the world’s leading research authority on pharmaceutical clinical trials and intelligence recently completed a comprehensive review of clinical trial starts in the autoimmune/inflammation therapeutic area to uncover trends and patterns regarding drug development.
Omnicare Clinical Research Acquired By Nautic Partners, LLC
Omnicare Clinical Research (CR), a leading global, full-service contract research organization (CRO), announced recently that it has been acquired by Nautic Partners, LLC, a private equity firm based in Providence, R.I.
Alzheimer’s Disease Neuroimaging Initiative (ADNI) In Clinical Trials
Last week was a highpoint for the ADNI group with the presentation of the Nancy and Ronald Reagan award at the national Alzheimer’s Disease Gala in Washington DC, and the face to face meeting of the ADNI researchers and private partners in LA preceding the American Academy of Neurology meeting in Hawaii. I had the privilege of attending the first two with my colleague Dr. Chahin Pachai. He then went on to Hawaii (Note to self – next time get Chahin to write a blog and I’ll go to Hawaii)!
Oncolytics Biotech Inc. Meets Primary Endpoint For First Part Of U.S. Phase 2 Pancreatic Cancer Clinical Trial
Oncolytics Biotech Inc. ("Oncolytics") recently announced preliminary results from a U.S. Phase 2 clinical trial (REO 017) using intravenous administration of REOLYSIN in combination with gemcitabine (Gemzar) in patients with advanced pancreatic cancer.
Researchers Test Inhalable Measles Vaccine
Sustained high vaccination coverage is key to preventing deaths from measles. Despite the availability of a vaccine,
BioClinica Partners With Symbiance
BioClinica, Inc.,a global provider of clinical trial
management solutions, recently announced it has established a strategic partnership with Symbiance Inc., a specialty contract research organization (CRO) based in Princeton Junction, New Jersey. Symbiance concentrates in therapeutic areas relevant to pharmaceutical and biotechnology companies with particular focus in oncology and CNS.
Adamis Pharmaceuticals Announces Phase 3 Meets Primary Endpoint
Adamis Pharmaceuticals Corporation announced the successful completion of a Phase 3 contraceptive trial of the company's contraceptive gel product candidate named Savvy® (C31G).
Juvenile Diabetes Research Foundation And Amylin Pharmaceuticals Partner To Investigate Metreleptin As Potential Therapy To Improve Blood Glucose Control In Type 1 Diabetes
The Juvenile Diabetes Research Foundation (JDRF) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced today that they entered into a research collaboration agreement to provide financial support for a clinical proof-of-concept study to investigate the effects of metreleptin, an analog of the human hormone leptin, in patients with type 1 diabetes. Researchers at The University of Texas (UT) Southwestern Medical Center will conduct the study.
Michael J. Fox Foundation Launches Parkinson's Progression Markers Initiative (PPMI)
The Michael J. Fox Foundation has launched the Parkinson’s Progression Markers Initiative (PPMI) (www.michaeljfox.org/PPMI), the first-ever large-scale clinical study exclusively focused on identifying and validating Parkinson’s disease biomarkers.
Harbor BioSciences Apoptone® For Prostate Cancer Shows A Partial Overall Response
Harbor BioSciences, Inc. (Nasdaq:HRBR) a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released new positive data from its ongoing Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.